The identification of high-risk stage II colon cancers is key to the selection of patients who require adjuvant treatment after surgery. Microarray-based multigeneexpression signatures derived from stem cells and progenitor cells hold promise, but they are difficult to use in clinical practice.
D uring the past decade, disease-free survival among patients with stage III colon cancer has increased significantly owing to the introduction of new adjuvant chemotherapy regimens. [1] [2] [3] This therapeutic success, however, has not translated into longer diseasefree survival among patients with earlier-stage (stage I or II) cancer. 4 The lack of simple, reliable criteria for the identification of patients with early-stage disease who are at high risk for relapse has made it difficult to identify patients in whom the hazards of multiagent chemotherapy may be offset by benefits with respect to diseasespecific survival. [4] [5] [6] [7] [8] [9] To address this problem, researchers have explored the possibility of stratifying patients with colon cancer according to the gene-expression profile of their tumor tissues, and they have developed multigene-expression signatures that can be used to identify high-risk colon cancers. [10] [11] [12] [13] [14] [15] Although gene-expression signatures hold promise, they are difficult to use in clinical practice 16 and are often not predictive of benefit from adjuvant chemotherapy. 17 Among the gene-expression signatures with the greatest promise are those derived from stem cells and progenitor cells. 18, 19 Therefore, we initiated a systematic search for a biomarker that could be used to identify undifferentiated tumors (i.e., tumors depleted of cells with a mature phenotype) by means of immunohistochemical analysis.
To perform this search, we adopted a bioinformatics approach using Boolean logic. This approach, which was designed to discover developmentally regulated genes, 20, 21 was used to identify genes with expression in colon cancer that was negatively linked to the activated leukocyte-cell adhesion molecule (ALCAM/CD166). This marker of immature colon epithelial cells is preferentially expressed at the bottom of colon crypts 22, 23 and on human colon-cancer cells with enriched tumorigenic capacity in mouse xenotransplantation models. 24 This screening test led us to identify caudaltype homeobox transcription factor 2 (CDX2) as a candidate biomarker of mature colon epithelial tissues. Using subgroup analysis involving retrospective patient cohorts, we evaluated the association of this biomarker with 5-year disease-free survival and benefit from adjuvant chemotherapy among patients with colon cancer (Fig. 1 ).
Me thods

Bioinformatics Analysis of Gene-Expression Array Databases
We searched for genes that fulfilled the "X-negative implies ALCAM-positive" Boolean relationship in a collection of 2329 human colon gene-expression array experiments ( Fig. S1 in Supplementary Appendix 1, available with the full text of this article at NEJM.org). This collection was downloaded from the National Center for Biotechnology Information (NCBI) Gene Expression Omnibus (GEO) repository (www . ncbi . nlm . nih . gov/ geo). The search was conducted with the use of Bool-eanNet software 20 with a false discovery rate of less than 0.0001 as a cutoff point for positive results ( Fig. S2 in Supplementary Appendix 1). Candidate genes were ranked according to the dynamic range of their expression levels ( Fig. S3 in Supplementary Appendix 1).
The relationship between CDX2 expression levels and other molecular features such as microsatellite instability and TP53 mutations was studied in ad hoc collections annotated with the respective information after tumor samples were stratified into CDX2-negative and CDX2-positive subgroups with the use of the StepMiner algorithm 25 (Fig. S4 and S5 in Supplementary Appendix 1). The relationship between CDX2 messenger RNA (mRNA) expression levels or ALCAM mRNA expression levels and disease-free survival was tested in a discovery data set of 466 patients. We A database containing 2329 human gene-expression arrays from both 214 normal colon tissue samples and 2115 colorectal-cancer tissue samples was mined to identify genes that fulfilled the "X-negative implies activated leukocyte-cell adhesion molecule (ALCAM)positive" Boolean implication. The search yielded 16 candidate genes, of which only 1 (CDX2) encoded for a clinically actionable biomarker. The association between CDX2 expression and disease-free survival was tested in two independent patient cohorts: a discovery data set (National Center for Biotechnology Information Gene Expression Omnibus [NCBI-GEO]) and a validation data set (Cancer Diagnosis Program of the National Cancer Institute [NCI-CDP] obtained this data set by pooling four NCBI-GEO data sets (GSE14333, GSE17538, GSE31595, and GSE37892) ( Fig. S6 in Supplementary Appendix 1). 12, 13, 26, 27 Patients were stratified into negative-to-low (negative) and high (positive) subgroups with regard to CDX2 and ALCAM gene-expression levels with the use of the StepMiner algorithm, implemented within the Hegemon 21 Step 1
Evaluation of CDX2 association with 5-yr disease-free survival in two independent data sets (discovery and validation) with use of multivariate analysis based on the Cox proportionalhazards method
Step 2
Evaluation of CDX2 association with benefit from adjuvant chemotherapy in a pooled database of historical cohorts of treated and untreated patients with use of Kaplan-Meier curves and interaction tests
Step 3
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Immunohistochemical Testing
Formalin-fixed, paraffin-embedded tissue sections were stained with 4 mg per milliliter of a mouse antihuman CDX2 monoclonal antibody that was previously validated for diagnostic applications (clone CDX2-88, BioGenex). 28, 29 The staining protocol was based on recommendations from the Nordic Immunohistochemical Quality Control organization (www.nordiqc.org), which suggests heat-induced antigen retrieval with Tris buffer and EDTA (pH 9.0) (Epitope Retrieval Solution pH9, Leica). 30 Tissue slides were stained on a Bond-Max automatic stainer (Leica), and antigen detection was visualized with the use of the Bond Polymer Refine Detection kit (Leica).
Analysis of Tissue Microarrays
Colon-cancer tissue microarrays, fully annotated with clinical and pathological information, were obtained from three independent sources: 367 patients in the Cancer Diagnosis Program of the National Cancer Institute (NCI-CDP), 1519 patients in the National Surgical Adjuvant Breast and Bowel Project (NSABP) C-07 trial (NSABP C-07), and 321 patients in the Stanford Tissue Microarray Database (Stanford TMAD). A detailed description of the patient cohorts represented in each tissue microarray and of the scoring system used to evaluate CDX2 expression is provided in Figures S11 through S14 in Supplementary Appendix 1.
All tissue microarrays were scored for CDX2 expression in a blinded fashion. In cases in which tissue microarrays contained two tissue cores for a patient (i.e., two samples from distinct areas of the same tumor), the two cores were scored independently and paired at the end. If scores for the two samples were discordant, the final score for the tumor was upgraded to the higher score. All tumors in which the malignant epithelial component showed widespread nuclear expression of CDX2, either in all or a majority of cancer cells, were scored as CDX2-positive. All tumors in which the malignant epithelial component either completely lacked CDX2 expression or showed faint nuclear expression in a minority of malignant epithelial cells were scored as CDX2-negative.
The concordance between the scoring results obtained by two independent investigators was evaluated with the use of contingency tables and by calculation of Cohen's kappa indexes ( Fig. S15 in Supplementary Appendix 1). The association between CDX2 expression and survival outcomes was tested by a third investigator who did not participate in the scoring process.
Statistical Analysis
Patient subgroups were compared with respect to survival outcomes with the use of Kaplan-Meier curves, log-rank tests, and multivariate analyses based on the Cox proportional-hazards method. Differences in the frequency of CDX2-negative cancers across different subgroups were compared with the use of Pearson's chi-square test and by computation of odds ratios together with their 95% confidence intervals. Interactions between the biomarker (CDX2 status) and adjuvant chemotherapy were evaluated with the use of the Cox proportional-hazards method in a 2-by-2 factorial design (i.e., by testing for the presence of an interaction factor between the hazard rates of the two variables).
R esult s
Identification of CDX2
The first aim of this study was to identify an actionable biomarker of poorly differentiated colon cancers (i.e., tumors depleted of mature colon epithelial cells). An actionable biomarker is one for which a clinical-grade diagnostic test had already been developed. Using a software algorithm designed for the discovery of genes with expression patterns that are linked by Boolean relationships (BooleanNet), 20 we mined a database of 2329 human colon gene-expression array experiments, searching for genes that fulfilled the "X-negative implies ALCAM-positive" Boolean implication (i.e., genes with expression that was, at the same time, absent only in ALCAM-positive tumors and always present in ALCAM-negative tumors) ( Fig. S2 in Supplementary Appendix 1).
The search led to the identification of 16 candidate genes ( Fig. S3 in Supplementary Appendix 1). Of these genes, only 1 gene encoded a protein that could be studied by means of immunohistochemical analysis with the use of a clinical-grade diagnostic test: the homeobox transcription factor CDX2. 28, 29, 31 CDX2 is a master regulator of intestinal development and oncogenesis, 32, 33 and its expression is highly specific to the intestinal epithelium. 29 Colon cancers without CDX2 expression are often associated with an increased likelihood of aggressive features such as advanced stage, poor differentiation, vascular invasion, BRAF mutation, and the CpG island methylator phenotype (CIMP). [34] [35] [36] [37] [38] [39] A detailed analysis of the gene-expression re-lationship between CDX2 and ALCAM confirmed the existence of three gene-expression groups: CDX2-negative and ALCAM-positive, CDX2-positive and ALCAM-positive, and CDX2-positive and ALCAM-negative ( Fig. S2 in Supplementary Appendix 1). Lack of CDX2 expression was restricted to a small subgroup of 87 of 2115 colorectal cancers (4.1%). This subgroup was characterized by high levels of ALCAM expression ( Fig. S3 in Supplementary Appendix 1) and only partial overlap with tumors defined by microsatellite instability or TP53 mutations ( Fig. S4 and S5 in Supplementary Appendix 1). We thus proceeded to Analysis of CDX2 messenger RNA (mRNA) expression in the NCBI-GEO discovery data set revealed the presence of a minority subgroup of CDX2-negative colon cancers that were characterized by high ALCAM mRNA expression levels (Panel A) and that were associated with a lower rate of 5-year disease-free survival than CDX2-positive colon cancers (Panel B). In Panel A, each circle in the scatter plot represents one patient sample. The association between CDX2negative cancers and a lower rate of disease-free survival remained significant in a multivariate analysis that excluded tumor stage, tumor grade, age, and sex as confounding variables (Panel C). evaluate the association between CDX2 expression and disease-free survival in two independent patient data sets: the NCBI-GEO discovery data set and the NCI-CDP validation data set.
CDX2 Expression and Disease-free Survival in the NCBI-GEO Discovery Data Set
To evaluate the association between CDX2 expression and disease-free survival among patients in the NCBI-GEO discovery data set, we used the StepMiner algorithm to stratify the population of 466 patients into CDX2-negative and CDX2positive subgroups and then used Kaplan-Meier curves to compare the disease-free survival of the two subgroups (Fig. 2) . The analysis showed that the rate of 5-year disease-free survival was lower among the 32 patients (6.9%) with CDX2negative tumors than among the 434 (93.1%) with CDX2-positive tumors (41% vs. 74%, P<0.001). In a multivariate analysis that excluded age, sex, and tumor stage as confounding variables, the hazard ratio for disease recurrence among patients with CDX2-negative versus CDX2-positive tumors was 2.73 (95% confidence interval [CI], 1.58 to 4.72; P<0.001).
Within the NCBI-GEO discovery data set, data on only 216 patients were annotated with information on pathological grade (Table S1 in Supplementary Appendix 1). A multivariate analysis that was restricted to these 216 patients showed that CDX2-negative tumors were associated with a higher risk of recurrence than CDX2positive ones (hazard ratio, 3.44; 95% CI, 1.60 to 7.38; P = 0.002); the hazard ratio associated with the CDX2 status was higher than that associated with increasing pathological grade (hazard ratio, 0.99; 95% CI, 0.56 to 1.74; P = 0.96).
High levels of ALCAM expression had previously been shown to be associated with worse clinical outcomes. 23 Moreover, in the NCBI-GEO discovery data set, the rate of 5-year disease-free survival associated with ALCAM-positive tumors was moderately, but significantly lower than that associated with ALCAM-negative ones (67% vs. 78%, P = 0.048) ( Fig. S7 in Supplementary Appendix 1). Therefore, we evaluated whether the association between CDX2-negative tumors and a lower rate of disease-free survival could be explained by the fact that most CDX2-negative tumors were also ALCAM-positive. To this end, we used Hege-mon software 21 to stratify the NCBI-GEO population into three subgroups (CDX2-negative and ALCAM-positive, CDX2-positive and ALCAM-positive, and CDX2-positive and ALCAM-negative) and then compared their clinical outcomes ( Fig. S8 and S9 in Supplementary Appendix 1) .
The results showed that CDX2-negative and ALCAM-positive tumors were associated with a lower rate of 5-year disease-free survival than CDX2-positive and ALCAM-positive and CDX2-positive and ALCAM-negative tumors. A similar set of tests also indicated that when compared side by side with the use of multivariate analysis, the hazard ratios for disease recurrence associated with the CDX2 and ALCAM grouping system were higher than those associated with the "intestinal stem-cell" gene-expression signature 19 (Fig. S10 in Supplementary Appendix 1).
CDX2 Expression and Disease-free Survival in the NCI-CDP Validation Data Set
To evaluate the robustness of our findings, we decided to test whether they could be reproduced in an independent data set, 40 and we chose to analyze a human colon-cancer tissue microarray obtained from the NCI-CDP. This microarray was explicitly designed to contain a balanced distribution of patients with and without tumor recurrence, as well as with a relatively homogeneous long-term follow-up, with the aim to maximize the statistical power to find associations between biomarkers and clinical outcomes.
Figure 3 (facing page). Relationship between CDX2 Protein Expression and Disease-free Survival in the NCI-CDP Validation Data Set.
Analysis of CDX2 protein expression in the NCI-CDP validation data set confirmed the existence of a minority subgroup of CDX2-negative cancers (Panel A) that lacked the distinctive CDX2 nuclear expression that is characteristic of epithelial cancer cells in the majority of colon cancers (Panel B). CDX2-negative cancers were associated with a lower rate of 5-year disease-free survival than CDX2-positive cancers (Panel C). The association between the absence of CDX2 expression and a lower rate of 5-year disease-free survival was confirmed by means of a multivariate analysis (based on the Cox proportional-hazards method) that excluded tumor stage, tumor grade, age, and sex as confounding variables (Panel D). CDX2-negative tumors were associated with a lower rate of survival independent of their subclassification with regard to low or intermediate (G1 or G2) or high (G3 or G4) pathological grade (Panel E). To evaluate CDX2 protein expression, we used immunohistochemical analysis with an anti-CDX2 monoclonal antibody that had previously been validated for diagnostic purposes. 28, 29 Analysis of stained sections confirmed the presence of a minority subgroup of cancers that lacked expression of CDX2 protein in malignant epithelial cells, as compared with the majority of samples that had intense nuclear staining (Fig. 3) . On the basis of these results, we stratified the patient cohort into two subgroups: CDX2-negative (48 of 366 patients [13%]) and CDX2-positive (318 of 366 patients [87%]). A description of the scoring system and its performance in terms of interobserver agreement is provided in Figures S14 and S15 in Supplementary Appendix 1.
CDX2-negative tumors were associated with a worse prognosis than were CDX2-positive tumors, with lower rates of 5-year disease-free survival (48% vs. 71%, P<0.001) ( Fig. 3) , overall survival (33% vs. 59%, P<0.001) ( Fig. S16 in Supplementary Appendix 1), and disease-specific survival (45% vs. 72%, P<0.001) ( Fig. S16 in Supplementary Appendix 1). The association remained significant in multivariate analyses that excluded age, sex, tumor stage, and tumor grade as confounding variables: in the analysis of diseasefree survival, the hazard ratio for disease recurrence associated with CDX2-negative tumors as compared with CDX2-positive tumors was 2.42 (95% CI, 1.36 to 4.29; P = 0.003); in the analysis of overall survival, the hazard ratio for death was 1.79 (95% CI, 1.18 to 2.71; P = 0.006); and in the analysis of disease-specific death, the hazard ratio for death was 2.09 (95% CI, 1.22 to 3.58; P = 0.007).
CDX2-negative status was more common among tumors with a high pathological grade ( Fig. S17 in Supplementary Appendix 1) . However, CDX2-negative tumors were associated with a lower rate of survival irrespective of their low or intermediate (G1 or G2) or high (G3 or G4) pathological grade -a finding consistent with the results of the multivariate analysis ( Fig. 3 , and Fig. S17 in Supplementary Appendix 1).
CDX2 Expression and Survival among Patients with Stage II Disease
To evaluate our findings with respect to the prognosis among patients with early-stage colon cancer, we decided to study the association between the CDX2-negative phenotype, assessed at either the mRNA or protein level, and disease-free survival among patients with stage II disease. Stage II CDX2-negative tumors were associated with a lower rate of 5-year disease-free survival than were stage II CDX2-positive tumors in both the NCBI-GEO discovery data set (49% vs. 87%, P = 0.003) ( Fig. 4 ) and the NCI-CDP validation data set (51% vs. 80%, P = 0.004) (Fig. 4) .
We found similar associations with respect to overall survival (40% among patients with CDX2negative tumors vs. 70% among those with CDX2-positive tumors, P<0.001) ( Fig. S18 in Supplementary Appendix 1) and disease-specific survival (66% vs. 89%, P = 0.005) ( Fig. S18 in Supplementary Appendix 1) . These associations were not confounded by risk factors that are known to affect survival rates among patients with stage II colon cancer, such as the depth of invasion of the primary tumor (T3 vs. T4) ( Fig.  S19 in Supplementary Appendix 1) and the number of lymph nodes resected at surgery (≥12 vs. <12) ( Fig. S19 in Supplementary Appendix 1). However, in each of the two data sets, only 15 patients with stage II CDX2-negative disease were identified.
CDX2 Expression and Benefit from Adjuvant Chemotherapy
To evaluate whether patients with CDX2-negative tumors might benefit from adjuvant chemotherapy, we investigated the association between CDX2 status, assessed at either the mRNA or protein level, and disease-free survival among patients who either did or did not receive adjuvant chemotherapy. A preliminary test involving cohorts of patients with stage III disease in both the discovery and validation data sets suggested a strong association between the use of adjuvant chemotherapy and a higher rate of disease-free survival in the CDX2-negative subgroups ( Fig. S20 in Supplementary Appendix 1) .
We thus decided to validate this observation in an expanded database of 669 patients with stage II colon cancer and 1228 patients with stage III colon cancer. We obtained this database by pooling data from four independent patient cohorts (NCBI-GEO, NCI-CDP, NSABP C-07, and Stanford TMAD); these data were annotated with information about adjuvant chemotherapy ( Fig. 1) . A detailed description of all patient data sets used for this experiment is provided in Figure S6 and Figures S11, S12, and S13 in Supplementary Appendix 1.
The results confirmed that treatment with 219 CDX2 as a Biomarker in Colon Cancer adjuvant chemotherapy was associated with a higher rate of disease-free survival in both the stage II subgroup (91% with chemotherapy vs. 56% with no chemotherapy, P = 0.006) and the stage III subgroup (74% with chemotherapy vs. 37% with no chemotherapy, P<0.001) of the CDX2-negative patient population (Fig. 5) . A test for the interaction between the biomarker and the treatment revealed that the benefit observed in CDX2-negative cohorts was superior to that observed in CDX2-positive cohorts in both the stage II subgroup (P = 0.02 for the interaction) and the stage III subgroup (P = 0.005 for the interaction). The association between CDX2-negative status and benefit from adjuvant chemotherapy was not confounded by risk factors that are known to affect the survival rates among patients with stage II and stage III disease. These risk factors include the depth of invasion of the primary tumor (T3 vs. T4), the number of lymph nodes resected at surgery (≥12 vs. <12), and the number of metastatic lymph nodes (N1 vs. N2) (Figs. S21 through S24 in Supplementary Appendix 1).
Discussion
Prognostic biomarkers are key to the risk stratification of patients with colon cancer and the decision to recommend adjuvant chemotherapy in patients with early-stage disease. 6 Currently, tumor stage, tumor grade, and microsatellite instability remain the most important among a handful of prognostic variables that are considered in the development of algorithms for the treatment of patients with early-stage colon cancer. 5, 9 Prognostic variables such as lymphovascular invasion by cancer cells and perineural invasion by cancer cells, though very promising, have proved difficult to standardize because of technical problems inherent in the visual analysis and subjective definition of these features. 6 Microarray-derived gene-expression signatures from stem cells and progenitor cells have also shown promise, 19 but they are often difficult to translate into clinical tests. 16 Overall, it has proved difficult to identify a prognostic biomarker that is also predictive of benefit from adjuvant chemotherapy. 7, 8, 17 In this study, we applied a bioinformatics approach to the discovery of prognostic biomarkers in human cancer. We assembled a large database of gene-expression array experiments involving human colorectal cancers and searched for genes with differential expression, defined by a Boolean relationship with respect to a wellestablished differentiation marker, across the patient population. The concept behind this approach was that genes associated with differentiation processes (e.g., transcription factors involved in the regulation of stem-cell self-renewal, lineage commitment, or both) could be identified as single prognostic biomarkers that could be used to stratify tumors on the basis of a In the NCBI-GEO discovery data set (Panel A), CDX2-negative cancers were associated with a rate of 5-year disease-free survival that was lower than the rate associated with CDX2-positive cancers. In the NCI-CDP validation data set (Panel B), CDX2-negative cancers were associated with a rate of 5-year disease-free survival that was lower than the rate associated with CDX2-positive cancers. molecular definition of their differentiation status and to recapitulate the prognostic information contained in complex multigene-expression signatures obtained from populations of stem cells and progenitor cells.
Using this approach, we identified CDX2 as a biomarker with expression that has been found to be absent in a minority subgroup of colon cancers that are characterized by high levels of ALCAM, a molecule that is expressed at the highest levels at the bottom of human colonic crypts 22, 23 and on human colon-cancer cells with enriched tumorigenic capacity in mouse xenotransplantation models. 24 We then performed a test to determine whether CDX2-negative cancers might be associated with a worse progno- The relationship between CDX2 expression and benefit from adjuvant chemotherapy was evaluated in a pooled database of 669 patients with stage II disease (Panel A) and 1228 patients with stage III disease (Panel B) from four independent data sets (NCBI-GEO, NCI-CDP, NSABP C-07, and Stanford TMAD). Among all patients with stage II disease in the entire database, treatment with adjuvant chemotherapy was not associated with a higher rate of 5-year disease-free survival. However, treatment with adjuvant chemotherapy was strongly associated with a higher rate of 5-year disease-free survival in the CDX2-negative subgroup, but it was not associated with a higher rate of 5-year disease-free survival in the CDX2-positive subgroup. Among patients with stage III disease, treatment with adjuvant chemotherapy was associated with a higher rate of 5-year disease-free survival in the entire database and in both the CDX2-negative and CDX2-positive subgroups. A test for an interaction between the biomarker and the treatment indicated that in both stage II and stage III disease, the benefit associated with adjuvant chemotherapy was superior among CDX2-negative patients than among CDX2-positive patients.
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No. at Risk sis. The results revealed that without adjuvant chemotherapy, CDX2-negative tumors were associated with a lower rate of disease-free survival than CDX2-positive tumors across independent data sets. This effect was independent of many known risk factors, including pathological grade. Previous studies had indicated that CDX2negative tumors are often associated with several adverse prognostic variables (e.g., advanced stage, poor differentiation, vascular invasion, BRAF mutation, and CIMP-positive status). 31, [35] [36] [37] [38] We hypothesize that the prognostic effect associated with an absence of CDX2 expression could be explained by its aggregate capacity to function as a single biomarker for multiple biologic risk factors, under the common theme of a highly immature progenitor-cell phenotype.
Finally, our results indicate that patients with stage II or stage III CDX2-negative colon cancer might benefit from adjuvant chemotherapy and that adjuvant chemotherapy might be a treatment option for patients with stage II CDX2-negative disease, who are commonly treated with surgery alone. Given the exploratory and retrospective design of our study, these results will need to be further validated. We advocate for these findings to be confirmed within the framework of randomized, clinical trials, in conjunction with genomic DNA sequencing studies.
